The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study-Reference-Cited by-同舟云学术

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

Published:2022-12 Issue:12 Volume:3 Page:100427
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Benjamin David J.,Chen Shuai,Eldredge Joanna B.,Schokrpur Shiruyeh,Li Debory,Quan Zhikuan,Chan Jason W.,Cummings Amy L.,Daly Megan E.,Goldman Jonathan W.,Gubens Matthew A.,Harris Jeremy P.,Onaitis Mark W.,Zhu Viola W.,Patel Sandip P.,Kelly Karen

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Treatment of advanced non–small-cell lung cancer: from chemotherapy to chemoimmunotherapy;Pirker;J Oncol Pract,2018

2. Targeted therapy in lung cancer: are we closing the gap in years of life lost?;Benjamin;Cancer Med,2022

3. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors;Akbay;Cancer Discov,2013

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis;BMC Cancer;2024-07-15

2. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer;Cancers;2024-06-12

3. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non–Small-Cell Lung Cancer With Novel Driver Alterations;Clinical Lung Cancer;2023-11

4. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers;Targeted Oncology;2023-11

5. Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations;JTO Clinical and Research Reports;2023-10